Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

University Hospital Center (CHU)

Status: Completed

Conditions: Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

Treatments: Drug: Anti-PD-1 or anti-PD-L1

Study type: Observational

Funder types: Other

Identifiers

NCT04609930

RECHMPL20_0583

Details and patient eligibility

About

The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.

Enrollment: 143 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Electronic patient file "DxCare" at the University Hospitals of Montpellier
• Patient has received anti-PD-1 immunotherapy --AND/OR -- anti-PD-L1 immunotherapy according to central pharmacy records

Exclusion criteria

• No mention of % eosinophilia in the patient file

Trial design

143 participants in 1 patient group

The study population

Description:

Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1

Treatment:

Drug: Anti-PD-1 or anti-PD-L1